Novel strategies to lower Lp(a)

10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD - San Diego, CA, USA - Online CME

Video navigation menu

Pathophysiology 00:39
RNA therapeutics for Lp(a) therapy 02:21
Early studies with antisense mediated Lp(a) lowering 05:26
AKCEA-APO(a)-Lrx phase 2 trials 13:07
CV outcome trial targeting Lp(a) 13:40

Educational information

This presentation by prof. Sam Tsimikas, MD was part of the EBAC-accredited symposium "Lp(a), a new lipid frontier in CV risk management and target for therapy" held during the virtual ESC Congress 2020

Faculty

Sam Tsimikas, Professor of Medicine and Director of Vascular Medicine at the University of California San Diego School of Medicine, San Diego, CA, USA.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Sanofi and Novartis.

Click here for the meeting report Click here for the slides of this presentation

Online-CME

This is available as accredited online CME for members. Click the button below to enroll:

Enroll

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.